Postby Rock_Robster » Wed Nov 20, 2019 2:37 am
The criteria for HAI are usually hospital policy-driven. In some centres this means no metastatic disease outside the liver; others (like MSK & NIH) might be ok with some lung stuff if it’s minor and stable. I’ve not heard of anywhere taking on synchronous peri mets, but please don’t take that on any good authority.
Criteria for liver resection are constantly evolving and very surgeon-dependent. However some common ones are:
- The ability to preserve 25-35% of healthy contiguous liver mass
- The ability to achieve a margin of at least 1mm
- Ability to preserve or reconstruct major vasculature (eg hepatic artery, portal vein, etc)
- For some surgeons, extrahepatic disease is an issue. Others might be ok with organs that could also be treated curatively (eg lungs), but might hesitate with distant nodal disease (particularly the hepatic nodes)
Depending on how far “under” 3cm they are, the remaining spots might also be possible candidates for ablation rather than resection. Ultimately not much of these are hard-and-fast things; the best bet is to get to a high-volume, aggressive surgeon at a major centre and get their opinion directly.
It sounds like you’ve done a decent job of ruling out the omentum mets as a current issue; and if you have liver-limited disease you should get a much more positive reception from liver surgeons, and potentially a path to curative treatment. If they want an abdo scope to be sure then I guess you could do that too (or maybe they could do at the same time as liver surgery). If resectable now, then it seems more likely you would do surgery first then consider adjuvant HAI to reduce recurrence risk (if it’s available where you are).
Best of luck,
Rob
41M Australia
2018 Dx RC
G2 EMVI LVI, 4 liver mets
pT3N1aM1a Stage IVa MSS NRAS G13R
CEA 14>2>32>16>19>30>140>70
11/18 FOLFOX
3/19 Liver resection
5/19 Pelvic IMRT
7/19 ULAR
8/19 Liver met
8/19 FOLFOX, FOLFOXIRI, FOLFIRI
12/19 Liver resection
NED 2 years
11/21 Liver met, PALN, lung nodules
3/22 PVE, lymphadenectomy, liver SBRT
10/22 PALN SBRT
11/22 Liver mets, peri nodule. Xeloda+Bev
4/23 XELIRI+Bev
9/23 ATRIUM trial
12/23 Modified FOLFIRI+Bev
3/24 VAXINIA (CF33 + hNIS) trial